自体造血干细胞移植在滤泡性淋巴瘤中的作用研究进展。
Update on the role of autologous hematopoietic stem cell transplantation in follicular lymphoma.
机构信息
Servicio de Hematología: Hospital Universitario e Instituto Biosanitario (IBSAL) de Salamana . Paseo de San Vicente 37007 Salamanca, Spain.
出版信息
Mediterr J Hematol Infect Dis. 2012;4(1):e2012074. doi: 10.4084/MJHID.2012.074. Epub 2012 Nov 7.
Abstract
Follicular lymphoma (FL) remains incurable despite advances in new strategies of treatment, including monoclonal antibodies (MoAb). Except for early stages, FL is characterized by responses to treatments and systematic relapses. The main objective in this disease is to achieve a better progression free survival (PFS) and to increase overall survival (OS), mainly in young patients. In order to improve the results of conventional chemotherapy, autologous stem cell transplant (ASCT) is a feasible treatment in these patients. In this moment, ASCT is not recommended as first line treatment, except for transformed FL, but is a good strategy as salvage therapy with an improved PFS and OS. New drugs have been introduced to enhance responses of ASCT, but nowadays they are not part of conventional conditioning regimen.
摘要
滤泡性淋巴瘤 (FL) 尽管在新的治疗策略方面取得了进展，包括单克隆抗体 (MoAb)，但仍然无法治愈。除了早期阶段，FL 的特征是对治疗有反应且会系统性地复发。在这种疾病中，主要目标是实现更好的无进展生存期 (PFS) 和增加总生存期 (OS)，主要是在年轻患者中。为了提高常规化疗的效果，自体干细胞移植 (ASCT) 是这些患者可行的治疗方法。目前，ASCT 不建议作为一线治疗，除非是转化型 FL，但作为挽救疗法，ASCT 具有改善的 PFS 和 OS，是一种很好的策略。已经引入了新的药物来增强 ASCT 的反应，但目前它们不属于常规预处理方案。
相似文献
1
Update on the role of autologous hematopoietic stem cell transplantation in follicular lymphoma.自体造血干细胞移植在滤泡性淋巴瘤中的作用研究进展。
Mediterr J Hematol Infect Dis. 2012;4(1):e2012074. doi: 10.4084/MJHID.2012.074. Epub 2012 Nov 7.
2
High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.成人滤泡性淋巴瘤采用自体干细胞移植高剂量疗法与化疗或免疫化疗的比较
Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD007678. doi: 10.1002/14651858.CD007678.pub2.
3
A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.对复发、侵袭性、转化型和非转化型滤泡性淋巴瘤进行早期和晚期自体造血干细胞移植的15年分析。
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64. doi: 10.1016/j.bbmt.2007.04.009.
4
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.自体干细胞移植治疗滤泡性淋巴瘤：无论移植前是否使用利妥昔单抗，均有良好的长期生存获益。
Biol Blood Marrow Transplant. 2017 Oct;23(10):1631-1640. doi: 10.1016/j.bbmt.2017.05.021. Epub 2017 May 19.
5
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.自体干细胞移植治疗滤泡性淋巴瘤早期进展患者：德国低级别淋巴瘤研究组两项随机试验的随访研究。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1172-1179. doi: 10.1016/j.bbmt.2018.03.022. Epub 2018 Mar 29.
6
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era.新药时代自体和异基因干细胞移植在滤泡性淋巴瘤中的作用
Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016045. doi: 10.4084/MJHID.2016.045. eCollection 2016.
7
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.自体与减低强度异基因造血细胞移植治疗首次完全缓解或部分缓解后化疗敏感的滤泡性非霍奇金淋巴瘤患者。
Biol Blood Marrow Transplant. 2011 Jul;17(7):1051-7. doi: 10.1016/j.bbmt.2010.11.004. Epub 2010 Nov 10.
8
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.利妥昔单抗时代自体造血干细胞移植后复发性滤泡性淋巴瘤的临床特征和结局。
Hematol Oncol. 2020 Apr;38(2):137-145. doi: 10.1002/hon.2713. Epub 2020 Jan 30.
9
Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.自体干细胞移植治疗复发或难治性滤泡性淋巴瘤后的持久无事件生存：近期利妥昔单抗暴露和低危滤泡性淋巴瘤国际预后指数评分的积极影响。
Leuk Lymphoma. 2011 Nov;52(11):2124-9. doi: 10.3109/10428194.2011.594925. Epub 2011 Jul 8.
10
Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.滤泡性淋巴瘤的自体和异基因造血干细胞移植
Expert Opin Biol Ther. 2016;16(1):57-66. doi: 10.1517/14712598.2016.1096341. Epub 2015 Oct 29.
本文引用的文献
1
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.强化治疗联合自体造血干细胞移植（ASCT）与常规治疗作为滤泡淋巴瘤一线治疗的比较：一项荟萃分析。
Hematol Oncol. 2013 Mar;31(1):29-33. doi: 10.1002/hon.2015. Epub 2012 Apr 4.
2
High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.成人滤泡性淋巴瘤采用自体干细胞移植高剂量疗法与化疗或免疫化疗的比较
Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD007678. doi: 10.1002/14651858.CD007678.pub2.
3
Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.自体干细胞移植治疗滤泡性淋巴瘤：系统评价和荟萃分析。
J Natl Cancer Inst. 2012 Jan 4;104(1):18-28. doi: 10.1093/jnci/djr450. Epub 2011 Dec 21.
4
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.利妥昔单抗时代转化型非霍奇金淋巴瘤的大剂量化疗和自体干细胞移植。
Leuk Lymphoma. 2012 May;53(5):830-5. doi: 10.3109/10428194.2011.631637. Epub 2011 Dec 6.
5
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.伊布替尼替昔单抗（泽布替尼）联合 BEAM（Z-BEAM）预处理方案加自体造血干细胞移植治疗复发或难治性低度 CD20 阳性 B 细胞淋巴瘤：一项 GELA Ⅱ期前瞻性研究。
Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):212-8. doi: 10.1016/j.clml.2011.03.007. Epub 2011 Apr 9.
6
Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.在 GELA/GOELAMS FL2000 研究中，在首次复发时使用自体干细胞移植对初治和先前接受利妥昔单抗治疗的滤泡性淋巴瘤患者的影响。
Haematologica. 2011 Aug;96(8):1128-35. doi: 10.3324/haematol.2010.030320. Epub 2011 Apr 12.
7
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.大剂量化疗联合自体造血干细胞支持治疗组织学转化的 B 细胞非霍奇金淋巴瘤：一项挪威多中心 II 期研究。
Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17.
8
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响（PRIMA）：一项 3 期随机对照试验。
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
9
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.利妥昔单抗维持治疗复发/难治性滤泡性非霍奇金淋巴瘤：EORTC 20981 期随机分组研究的长期结果。
J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.
10
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.细胞毒治疗联合造血干细胞移植在滤泡淋巴瘤治疗中的作用：基于循证的综述。
Biol Blood Marrow Transplant. 2010 Apr;16(4):443-68. doi: 10.1016/j.bbmt.2010.01.008. Epub 2010 Jan 28.
Zotero 插件